The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells

被引:25
作者
Baptiste N. [1 ]
Friedlander P. [1 ]
Chen X. [1 ]
Prives C. [1 ]
机构
[1] Department of Biological Sciences, Columbia University, New York
关键词
Anti-neoplastics; Apoptosis; p53; Proline-rich domain;
D O I
10.1038/sj.onc.1205015
中图分类号
学科分类号
摘要
In some cell types either DNA damage or p53 expression leads to minimal cell death, while combining the two leads to a strong apoptotic response. To further understand features of p53 that contribute to this increased cell death we used clones of H1299 cells that express wild-type or several mutant forms of p53 under a tetracycline-regulated promoter. In these cells the induction of wild-type p53 leads to significant apoptosis only when combined with exposure to a number of chemotherapeutic agents. A common target of p53, p21, is itself not sufficient to cause apoptosis in the presence of these chemotherapeutic compounds. Many agents also effectively increase cell death when a transcriptionally-defective p53, p53[gln22ser23], is induced, although a dramatic exception is treatment with 5-FU, which strongly cooperates with wild-type but not p53[gln22ser23]. Our results with 5-FU thus show that genetically separable functions of p53 are involved in its ability to respond to DNA-damaging agents to induce apoptosis. Notably as well, deleting the C-terminal 30 amino acids of p53 does not affect this cooperative effect with DNA-damaging agents. By contrast, a p53 mutant lacking the PXXP-domain between residues 60-90, while at least partially transcriptionally-competent, cannot be rendered apoptotic by any compounds that we tested. Thus the PXXP domain provides an essential component of the ability of p53 to respond to DNA-damaging agents to cause cell death.
引用
收藏
页码:9 / 21
页数:12
相关论文
共 115 条
  • [41] Haupt Y., Barak Y., Oren M., EMBO J., 15, pp. 1596-1606, (1996)
  • [42] Hermeking H., Lengauer C., Polyak K., He T.C., Zhang L., Thiagalingam S., Kinzler K.W., Vogelstein B., Mol. Cell. Biol., 1, pp. 3-11, (1997)
  • [43] Jayaraman J., Prives C., Cell, 81, pp. 1021-1029, (1995)
  • [44] Jayaraman L., Prives C., Cell. Mol. Life Sci., 55, pp. 76-87, (1999)
  • [45] Jimenez G.S., Nister M., Stommel J.M., Beeche M., Barcarse E.A., Zhang X.Q., O'Gorman S., Wahl G.M., Nat. Genet., 26, pp. 37-43, (2000)
  • [46] Kastan M.B., Zhan Q., El-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.J., Cell, 71, pp. 587-597, (1992)
  • [47] Ko L.J., Prives C., Genes Dev., 10, pp. 1054-1072, (1996)
  • [48] Kobayashi T., Consoli U., Andreeff M., Shiku H., Deisseroth A.B., Zhang W., Oncogene, 11, pp. 2311-2316, (1995)
  • [49] Lee H., Larner J.M., Hamlin J.L., Proc. Natl. Acad. Sci. USA, 94, pp. 526-531, (1997)
  • [50] Lee S., Elenbaas B., Levine A., Griffith J., Cell, 81, pp. 1013-1020, (1995)